Morgan Stanley Maintains Overweight on Avalyn Pharma, Raises Price Target to $57
Morgan Stanley analyst Judah Frommer maintains Avalyn Pharma (NASDAQ:AVLN) with a Overweight and raises the price target from $53 to $57.
Read original at benzingaStocks · News reference
Avalyn Pharma shares are trading higher despite worse-than-expected Q2 results, likely driven by AP01 trial enrollment completion, ERS Congress abstracts, and strong cash runway into 2029 with pipeline progress.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 12, 2026, 2:11 PM
- Checked
- Aug 12, 2026, 2:11 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Avalyn Pharma Q2 EPS $(0.65) Misses $(0.53) Estimate
Avalyn Pharma (NASDAQ:AVLN) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.53) by 22.64 percent.
Read original at benzinga8-K filing — Avalyn Pharma Inc. (AVLN)
Filed: 2026-08-12 AccNo: 0001193125-26-345807 Size: 295 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar